-
Optimization of Selective Mu Opioid Receptor Antagonists for the Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
… Objective/Rationale: In Parkinson’s disease, L-DOPA-induced dyskinesias (LID) are therapeutically limiting side effects …
-
New Data on Extended-Release Amantadine for Dyskinesia
April 26, 2017
… Over the past year or so, we've told you about a dyskinesia drug that is advancing toward U.S. Food and Drug … drug experienced not only a reduction in levodopa-induced dyskinesia (involuntary, uncontrolled movements that can …
-
Study of Dyskinesia Treatment Enrolls First Patient
November 11, 2013
… A study testing a new drug to treat levodopa-induced dyskinesia has enrolled its first patient. Avanir … AVP-923 to a placebo to test its efficacy in relieving dyskinesia, involuntary movements associated with long-term …
-
Validation of metabotropic glutamate-receptor type 5 as a target for the treatment of L-DOPA-induced dyskinesia in a macaque model of Parkinson´s disease
… antagonism of mGluR5 attenuates L-DOPA-induced dyskinesia (LID) in a pre-clinical model of Parkinson´s … inhibit the gradual development and long-term priming for dyskinesia as induced by chronic treatment with L-DOPA de …
-
Breaking News: New Dyskinesia Drug Submitted to FDA
October 31, 2016
… A new drug for levodopa-induced dyskinesia -- involuntary, uncontrolled movements that can … levels are meant to peak during the day, when control of dyskinesia is needed most, and decrease at night, when …
-
Just in Time Pre-clinical Resource for Evaluating Symptoms & Side Effects and/or Dyskinesia Treatments
… by the development of debilitating side effects such as dyskinesia. Mechanisms to rapidly test novel therapeutic … for Parkinson’s disease. … Symptoms & Side Effects … Dyskinesia … Pre-clinical Models … California … United …